Regression of post-transplant Kaposi's sarcoma using sirolimus

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1509-1512

  Kolhe, Nitin ^a,b   Mamode, N ^a   Van Der Walt, J ^b   Pattison, J ^a  

^a Department of Renal Medicine and Transplantation ^*  (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Kaposi's sarcoma; Rapamycin; Renaltransplant; Sirolimus

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; PREDNISOLONE; RAPAMYCIN;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CELLULITIS; CLINICAL PROTOCOL; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHADENOPATHY; PERITONEAL DIALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

CYCLOSPORINE; FEMALE; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; SARCOMA, KAPOSI; SIROLIMUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33749838384     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00815.x     Document Type: Article

References (16)

1. Hayward GS. Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 2003; 3: 1-3.
2. Zavos G, Bokos J, Papaconstantinou J et al. Study of 'de novo'malignancies among Greek renal transplant recipients. Transplant Proc 2003; 35: 1399-403.
3. Moosa MR. Kaposi's sarcoma in kidney transplant recipients: A 23-year experience. QJM 2005; 98: 205-14.
4. Penn I. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996; 28: 876-8.
5. Regamey N, Tamm M, Binet I et al. Transplantation-associated Kaposi's sarcoma: Herpesvirus 8 transmission through renal allografts. Transplant Proc 1999; 31: 922-3.
6. Sandrini S, Setti G, Bossini N et al. Cancer after kidney transplantation. G Ital Nefrol 2004; 21 (Suppl. 26): S67-73.
7. Haberal M, Karakayali H, Emiroglu R et al. Malignant tumors after renal transplantation. Artif Organs 2002; 26: 778-81.
8. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-26.
9. Herman M, Weinstein T, Korzets A et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14-20.
10. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4.
11. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-2.
12. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23.
13. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-9.
14. Luan FL, Ding R, Sharma VK et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-26.
15. Boffa DJ, Luan F, Thomas D et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004; 10 (1 Part 1): 293-300.
16. Garber K. Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst 2001; 93: 1519.